{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:10:29Z","timestamp":1788459029813,"version":"build-2803163510"},"reference-count":56,"publisher":"American Association for Cancer Research (AACR)","issue":"5","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA276374-01"],"award-info":[{"award-number":["CA276374-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016058"],"award-info":[{"award-number":["P30CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Disease recurrence is the main cause of treatment failure after CD19-directed chimeric antigen receptor (CAR) T cells, often due to CD19 antigen loss, stability, and\/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, and CD22 with an OX40 costimulatory domain. Preclinical studies demonstrated potent, antigen-specific cytotoxicity in in vitro and in vivo lymphoma models. We then conducted a first-in-human phase I trial in patients with relapsed\/refractory B-cell malignancies. Sixteen patients received infusions at a median vein-to-vein time of 7 days, at doses of 0.5 to 2 \u00d7 106 cells\/kg. No severe cytokine release syndrome or neurotoxicity occurred. The overall response rate was 50%, including complete responses in 83% of patients with lymphoma. The 1-year overall survival rate was 61%, with durable remissions observed in lymphoma. CAR T expansion did not correlate with dose or response. T-cell exhaustion in apheresis cells correlated with progressive disease. Trispecific CAR T cells are safe and potentially active in lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This first-in-human trial demonstrates that point-of-care manufactured trispecific CD19\/20\/22 CAR T cells with OX40 costimulation can be rapidly produced, safely administered, and induce durable remissions in relapsed B-cell lymphoma. Findings highlight multispecific targeting to mitigate antigen escape and identify T-cell exhaustion as a key biomarker guiding future CAR T optimization.<\/jats:p>\n                    <jats:p>See related commentary by Merz and Luttwak, p. 652<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0186","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:49:46Z","timestamp":1784044186000},"page":"711-725","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-3880","authenticated-orcid":false,"given":"Sumithira","family":"Vasu","sequence":"first","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7936-7547","authenticated-orcid":false,"given":"Nathan","family":"Denlinger","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0947-0597","authenticated-orcid":false,"given":"No-Joon","family":"Song","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."},{"name":"3Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8869-9107","authenticated-orcid":false,"given":"Danielle","family":"Elsberry","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8594-0998","authenticated-orcid":false,"given":"Qiuhong","family":"Zhao","sequence":"additional","affiliation":[{"name":"4The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2025-2585","authenticated-orcid":false,"given":"Lianbo","family":"Yu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 5 , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-5697","authenticated-orcid":false,"given":"Evandro D.","family":"Bezerra","sequence":"additional","affiliation":[{"name":"6Cleveland Clinic, Cleveland, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2364-1628","authenticated-orcid":false,"given":"Nicole","family":"Szuminski","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-7374","authenticated-orcid":false,"given":"Dina","family":"Schneider","sequence":"additional","affiliation":[{"name":"7Cartesian Therapeutics, Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-0657","authenticated-orcid":false,"given":"Pradyot","family":"Dash","sequence":"additional","affiliation":[{"name":"8Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4927-1602","authenticated-orcid":false,"given":"Louisa","family":"Wirthlin","sequence":"additional","affiliation":[{"name":"8Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03v7tx966","id-type":"ROR","asserted-by":"publisher"}],"name":"Huntsman Cancer Institute 9 Division of Hematology and Hematologic Malignancies, , University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Yazeed","family":"Sawalha","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-6085","authenticated-orcid":false,"given":"Shamama","family":"Nishat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-0856","authenticated-orcid":false,"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-4286","authenticated-orcid":false,"given":"Hazem E.","family":"Ghoneim","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-3607","authenticated-orcid":false,"given":"Gregory K.","family":"Behbehani","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy J.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-9836","authenticated-orcid":false,"given":"Karilyn","family":"Larkin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-6144","authenticated-orcid":false,"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[{"name":"10Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3567-9129","authenticated-orcid":false,"given":"Victoria","family":"Churchill","sequence":"additional","affiliation":[{"name":"4The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4627-2822","authenticated-orcid":false,"given":"Elizabeth","family":"George","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Nationwide Children\u2019s Hospital 11 Office of Research Regulatory Affairs, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9413-3637","authenticated-orcid":false,"given":"Margaret","family":"Lamb","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Nationwide Children\u2019s Hospital 12 Division of Hematology\/Oncology\/BMT, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 13 Department of Pediatrics, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Nationwide Children\u2019s Hospital 12 Division of Hematology\/Oncology\/BMT, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 13 Department of Pediatrics, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/003rfsp33","id-type":"ROR","asserted-by":"publisher"}],"name":"Nationwide Children\u2019s Hospital 14 Center for Childhood Cancer Research, Abigail Wexner Research Institute, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1521","authenticated-orcid":false,"given":"Wing Keung","family":"Chan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7883","authenticated-orcid":false,"given":"Ashley","family":"Krull","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-3467","authenticated-orcid":false,"given":"Rimas J.","family":"Orentas","sequence":"additional","affiliation":[{"name":"8Lentigen Technology Inc., A Miltenyi Biotec Company, Gaithersburg, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9791-3659","authenticated-orcid":false,"given":"Lynn","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-927X","authenticated-orcid":false,"given":"Zihai","family":"Li","sequence":"additional","affiliation":[{"name":"2Division of Medical Oncology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."},{"name":"3Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-4162","authenticated-orcid":false,"given":"Lapo","family":"Alinari","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"1Division of Hematology, The Ohio State University James Comprehensive Cancer Center and Solove Research Institute, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026090303070345100_bib1","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/jci85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2026090303070345100_bib2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026090303070345100_bib3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026090303070345100_bib4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2026090303070345100_bib5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"2026090303070345100_bib6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303070345100_bib7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/nejmoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2026090303070345100_bib8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/jco.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090303070345100_bib9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"Supplement_1","key":"2026090303070345100_bib10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"2026090303070345100_bib11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026090303070345100_bib12","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090303070345100_bib13","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2026090303070345100_bib14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2026090303070345100_bib15","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"2026090303070345100_bib16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"key":"2026090303070345100_bib17","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.cd-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"2026090303070345100_bib18","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol Ther"},{"key":"2026090303070345100_bib19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"2026090303070345100_bib20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2026090303070345100_bib21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"2026090303070345100_bib22","doi-asserted-by":"publisher","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22\u2013targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Translational Med"},{"key":"2026090303070345100_bib23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"2026090303070345100_bib24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4049\/jimmunol.164.1.107","article-title":"Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion","volume":"164","author":"Maxwell","year":"2000","journal-title":"J Immunol"},{"key":"2026090303070345100_bib25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/s1074-7613(01)00191-1","article-title":"OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"key":"2026090303070345100_bib26","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41375-025-02518-5","article-title":"Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T Chimeric Antigen Receptor (CAR) T cell therapy CC-98633\/BMS-986354 in participants with triple-class exposed multiple myeloma","volume":"39","author":"Ravi","year":"2025","journal-title":"Leukemia"},{"key":"2026090303070345100_bib27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.cd-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"2026090303070345100_bib28","doi-asserted-by":"publisher","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"2026090303070345100_bib29","doi-asserted-by":"publisher","first-page":"103138","DOI":"10.1016\/j.eclinm.2025.103138","article-title":"Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial","volume":"81","author":"Ghobadi","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026090303070345100_bib30","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"},{"key":"2026090303070345100_bib31","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"2026090303070345100_bib32","doi-asserted-by":"publisher","first-page":"eabb9726","DOI":"10.1126\/sciimmunol.abb9726","article-title":"T cell factor 1: a master regulator of the T cell response in disease","volume":"5","author":"Escobar","year":"2020","journal-title":"Sci Immunol"},{"key":"2026090303070345100_bib33","doi-asserted-by":"publisher","first-page":"e002555","DOI":"10.1136\/jitc-2021-002555","article-title":"Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies","volume":"9","author":"Tantalo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026090303070345100_bib34","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"2026090303070345100_bib35","doi-asserted-by":"publisher","first-page":"eabk1900","DOI":"10.1126\/scitranslmed.abk1900","article-title":"T(STEM)-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026090303070345100_bib36","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","article-title":"Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics","volume":"27","author":"Panch","year":"2019","journal-title":"Mol Ther"},{"key":"2026090303070345100_bib37","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"2026090303070345100_bib38","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"2026090303070345100_bib39","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"key":"2026090303070345100_bib40","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas","volume":"8","author":"Haydu","year":"2024","journal-title":"Blood Adv"},{"key":"2026090303070345100_bib41","doi-asserted-by":"publisher","first-page":"eadr2151","DOI":"10.1126\/scitranslmed.adr2151","article-title":"OX40-heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice","volume":"17","author":"Zhang","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026090303070345100_bib42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.vaccine.2005.07.108","article-title":"Regulation of CD4 T cell memory by OX40 (CD134)","volume":"24","author":"Salek-Ardakani","year":"2006","journal-title":"Vaccine"},{"key":"2026090303070345100_bib43","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR T(Reg) cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"2026090303070345100_bib44","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41467-019-08637-9","article-title":"A functional subset of CD8(+) T cells during chronic exhaustion is defined by SIRP\u03b1 expression","volume":"10","author":"Myers","year":"2019","journal-title":"Nat Commun"},{"key":"2026090303070345100_bib45","doi-asserted-by":"publisher","first-page":"eadg1094","DOI":"10.1126\/sciimmunol.adg1094","article-title":"TIM-3(+) CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies","volume":"9","author":"Minnie","year":"2024","journal-title":"Sci Immunol"},{"key":"2026090303070345100_bib46","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"2026090303070345100_bib47","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"2026090303070345100_bib48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/2326-6066.cir-14-0195","article-title":"Individual motile CD4(+) T cells can participate in efficient multikilling through conjugation to multiple tumor cells","volume":"3","author":"Liadi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026090303070345100_bib49","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/jco.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026090303070345100_bib50","doi-asserted-by":"publisher","first-page":"e00383-18","DOI":"10.1128\/mcb.00383-18","article-title":"CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum","volume":"38","author":"Bagashev","year":"2018","journal-title":"Mol Cell Biol"},{"key":"2026090303070345100_bib51","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41375-019-0580-z","article-title":"Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19","volume":"34","author":"Asnani","year":"2020","journal-title":"Leukemia"},{"key":"2026090303070345100_bib52","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"2026090303070345100_bib53","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.cd-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"2026090303070345100_bib54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40164-023-00437-8","article-title":"A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models","volume":"12","author":"Chan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2026090303070345100_bib55","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/bloodadvances.2023012073","article-title":"Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma","volume":"8","author":"Denlinger","year":"2024","journal-title":"Blood Adv"},{"key":"2026090303070345100_bib56","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0186\/3812578\/bcd-26-0186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0186\/3820626\/bcd-26-0186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/711\/3824972\/bcd-26-0186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/5\/711\/3824972\/bcd-26-0186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:07:13Z","timestamp":1788419233000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/5\/711\/787638\/Safety-and-Clinical-Outcomes-of-a-First-in-Human"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0186","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}